Heron Therapeutics (HRTX) Operating Expenses (2010 - 2026)

Heron Therapeutics has reported Operating Expenses for 17 years, with the latest figure at $28.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 5.66% year-over-year to $28.8 million; the trailing twelve-month figure through Mar 2026 stood at $117.6 million (up 3.71% YoY), and the FY2025 full-year result was $116.1 million, down 0.91% from the prior year.
• Operating Expenses for Q1 2026 stood at $28.8 million, down from $29.4 million in the prior quarter.
• The five-year high for Operating Expenses was $86.4 million in Q1 2022, with the low at $26.4 million in Q4 2024.
• Historically, Operating Expenses has averaged $40.6 million across 5 years, with a median of $32.0 million in 2024.
• The largest YoY upside for Operating Expenses was 19.75% in 2022 against a maximum downside of 49.11% in 2022.
• Heron Therapeutics' Operating Expenses stood at $37.8 million in 2022, then retreated by 8.44% to $34.6 million in 2023, then dropped by 23.69% to $26.4 million in 2024, then advanced by 11.57% to $29.4 million in 2025, then slipped by 2.01% to $28.8 million in 2026.
• The last three Operating Expenses figures came in at $28.8 million (Q1 2026), $29.4 million (Q4 2025), and $30.4 million (Q3 2025), per Business Quant data.